An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity
暂无分享,去创建一个
[1] Danielle A. Simmons,et al. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease , 2007, Glia.
[2] N. Wood,et al. Disruption of Peripheral Circadian Timekeeping in a Mouse Model of Huntington's Disease and Its Restoration by Temporally Scheduled Feeding , 2010, The Journal of Neuroscience.
[3] Rahul S. Rajan,et al. Specificity in intracellular protein aggregation and inclusion body formation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[4] D. Rubinsztein,et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. , 2001, Human molecular genetics.
[5] T. Hansen,et al. Huntington’s Disease Does Not Appear to Increase the Risk of Diabetes Mellitus , 2009, Journal of neuroendocrinology.
[6] J. Mandel,et al. A cellular model that recapitulates major pathogenic steps of Huntington's disease. , 1998, Human molecular genetics.
[7] F. Squitieri,et al. Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation , 2006, Mechanisms of Ageing and Development.
[8] L. Frati,et al. DNA instability in replicating Huntington's disease lymphoblasts , 2009, BMC Medical Genetics.
[9] F. Fornai,et al. Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells , 2011, Journal of Neural Transmission.
[10] T. Möller,et al. Distinct neuroinflammatory profile in post-mortem human Huntington's disease , 2009, Neuroreport.
[11] H. Lehrach,et al. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. , 2004, Molecular cell.
[12] Richard I. Morimoto,et al. Polyglutamine protein aggregates are dynamic , 2002, Nature Cell Biology.
[13] I. Kanazawa,et al. Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. , 1999, Neuroreport.
[14] J. Penney,et al. Huntingtin localization in brains of normal and Huntington's disease patients , 1997, Annals of neurology.
[15] A. Tobin,et al. A cell-based screen for drugs to treat Huntington's disease , 2004, Neurobiology of Disease.
[16] P. Brundin,et al. Synaptic dysfunction in Huntington’s disease: a new perspective , 2005, Cellular and Molecular Life Sciences CMLS.
[17] M. Guillermier,et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects , 2010, Human molecular genetics.
[18] M. Hayden,et al. Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene , 2003, Clinical genetics.
[19] J. Cooper,et al. Clinical correlates of mitochondrial function in Huntington's disease muscle , 2007, Movement disorders : official journal of the Movement Disorder Society.
[20] D. Housman. Gain of glutamines, gain of function? , 1995, Nature Genetics.
[21] M. MacDonald,et al. Amyloid Formation by Mutant Huntingtin: Threshold, Progressivity and Recruitment of Normal Polyglutamine Proteins , 1998, Somatic cell and molecular genetics.
[22] S. Radford,et al. Fibril Fragmentation Enhances Amyloid Cytotoxicity*♦ , 2009, The Journal of Biological Chemistry.
[23] A. Dehejia,et al. Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models , 2000, Neuroscience Letters.
[24] M. Memo,et al. Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways , 2009, Amino Acids.
[25] Ji-Yeon Shin,et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.
[26] L. Havel,et al. Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. , 2011, Human molecular genetics.
[27] M. Beal,et al. Impaired PGC-1alpha function in muscle in Huntington's disease. , 2009, Human molecular genetics.
[28] M. Beal,et al. Oxidative damage in Huntington's disease pathogenesis. , 2006, Antioxidants & redox signaling.
[29] E. Cattaneo,et al. Cholesterol dysfunction in neurodegenerative diseases: Is Huntington's disease in the list? , 2006, Progress in Neurobiology.
[30] S. Folstein,et al. Cognitive and Motor Correlates of Everyday Functioning in Early Huntington's Disease , 1993, The Journal of nervous and mental disease.
[31] Steven Finkbeiner,et al. Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular Pathogenesis , 2010, The Journal of Neuroscience.
[32] S. W. Davies,et al. Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.
[33] Elena Cattaneo,et al. Loss of normal huntingtin function: new developments in Huntington's disease research , 2001, Trends in Neurosciences.
[34] Martin Drozda,et al. Depletion of wild‐type huntingtin in mouse models of neurologic diseases , 2003, Journal of neurochemistry.
[35] J. O’Kusky,et al. Toward Understanding the Molecular Pathology of Huntington's Disease , 1997, Brain pathology.
[36] E. Cattaneo,et al. Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway , 2012, Neurobiology of Disease.
[37] A. Delacourte,et al. Association of corticobasal degeneration and Huntington's disease: Can Tau aggregates protect Huntingtin toxicity? , 2009, Movement disorders : official journal of the Movement Disorder Society.
[38] Erich E Wanker,et al. The hunt for huntingtin function: interaction partners tell many different stories. , 2003, Trends in biochemical sciences.
[39] S. Podolsky,et al. Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. , 1977, Gerontology.
[40] Andreas Matouschek,et al. Inefficient degradation of truncated polyglutamine proteins by the proteasome , 2004, The EMBO journal.
[41] Dimitri Krainc,et al. Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.
[42] S. Zeitlin,et al. Deletion of the triplet repeat encoding polyglutamine within the mouse Huntington's disease gene results in subtle behavioral/motor phenotypes in vivo and elevated levels of ATP with cellular senescence in vitro. , 2006, Human molecular genetics.
[43] A. Hackam,et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates , 1998, Nature Genetics.
[44] Peter Breuer,et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. , 2004, Molecular cell.
[45] George Q. Daley,et al. Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.
[46] J. Marsh,et al. A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis. , 2010, Biophysical journal.
[47] C. Ross,et al. Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation , 2003, Neuroreport.
[48] F. Giorgini,et al. Connecting the dots in Huntington's disease with protein interaction networks , 2005, Genome Biology.
[49] Emmanuel Brouillet,et al. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment , 2005, Neurobiology of Disease.
[50] L Gan,et al. HIP1 Functions in Clathrin-mediated Endocytosis through Binding to Clathrin and Adaptor Protein 2* , 2001, The Journal of Biological Chemistry.
[51] A. Morton,et al. Microglia density decreases with age in a mouse model of Huntington's disease , 2003, Glia.
[52] J. Caviston,et al. Huntingtin as an essential integrator of intracellular vesicular trafficking. , 2009, Trends in cell biology.
[53] T. Outeiro,et al. α‐Synuclein modifies huntingtin aggregation in living cells , 2012, FEBS letters.
[54] M. Hayden,et al. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain , 2007, Neurobiology of Disease.
[55] Xingshun Xu,et al. Loss of huntingtin-associated protein 1 impairs insulin secretion from pancreatic β-cells , 2011, Cellular and Molecular Life Sciences.
[56] M. H. Polymeropoulos,et al. Alpha synuclein in neurodegenerative disorders: Murderer or accomplice? , 1998, Nature Medicine.
[57] He Li,et al. Inhibition of neurite outgrowth and promotion of cell death by cytoplasmic soluble mutant huntingtin stably transfected in mouse neuroblastoma cells , 2008, Neuroscience Letters.
[58] D. Rubinsztein,et al. Alpha-synuclein overexpression promotes aggregation of mutant huntingtin. , 2000, The Biochemical journal.
[59] Hans Lehrach,et al. Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo , 1997, Cell.
[60] A. Sarmento-Ribeiro,et al. Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients. , 2008, Biochemical and biophysical research communications.
[61] J. Lucas,et al. Alpha-synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington ́ s disease , 2011 .
[62] A. Messer,et al. Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's Disease transgenic mice 1 Published on the World Wide Web on 15 April 1999. 1 , 1999, Brain Research.
[63] Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high‐capacity adenoviral vectors expressing truncated and full‐length huntingtin with polyglutamine expansion , 2008, The journal of gene medicine.
[64] Cheng Song,et al. Expression of Full-length Polyglutamine-expanded Huntingtin Disrupts Growth Factor Receptor Signaling in Rat Pheochromocytoma (PC12) Cells* , 2002, The Journal of Biological Chemistry.
[65] D. Housman,et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[66] Alexander Gerhard,et al. Microglial activation in presymptomatic Huntington's disease gene carriers. , 2005, Brain : a journal of neurology.
[67] M. Yoshimoto,et al. NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[68] L. Kaltenbach,et al. Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons , 2012, Neurobiology of Aging.
[69] Rama S. Verma,et al. An improved protocol for primary culture of cardiomyocyte from neonatal mice , 2008, In Vitro Cellular & Developmental Biology - Animal.
[70] Suzanne Tydlacka,et al. Differential Activities of the Ubiquitin–Proteasome System in Neurons versus Glia May Account for the Preferential Accumulation of Misfolded Proteins in Neurons , 2008, The Journal of Neuroscience.
[71] Yen F. Tai,et al. Imaging microglial activation in Huntington's disease , 2007, Brain Research Bulletin.
[72] M. Hayden,et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.
[73] Mark R. Segal,et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.
[74] J. Mazzola,et al. Reduction of glyceraldehyde‐3‐phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts , 2001, Journal of neurochemistry.
[75] S. Finkbeiner,et al. Serines 13 and 16 Are Critical Determinants of Full-Length Human Mutant Huntingtin Induced Disease Pathogenesis in HD Mice , 2009, Neuron.
[76] Hiroshi Kimura,et al. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state , 2006, Nature Cell Biology.
[77] A. Hackam,et al. Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[78] M. Beal,et al. Hunting-ton for New Proteases: MMPs as the New Target? , 2010, Neuron.
[79] D. Rubinsztein,et al. Microtubule disruption inhibits autophagosome-lysosome fusion: implications for studying the roles of aggresomes in polyglutamine diseases. , 2004, The international journal of biochemistry & cell biology.
[80] R. Schwarcz,et al. Histone Deacetylase Inhibition Modulates Kynurenine Pathway Activation in Yeast, Microglia, and Mice Expressing a Mutant Huntingtin Fragment* , 2008, Journal of Biological Chemistry.
[81] Andrew F Hill,et al. Tracking Mutant Huntingtin Aggregation Kinetics in Cells Reveals Three Major Populations That Include an Invariant Oligomer Pool* , 2010, The Journal of Biological Chemistry.
[82] J. Lucas,et al. α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease. , 2012, Human molecular genetics.
[83] K. Wilkinson,et al. Modulating huntingtin half‐life alters polyglutamine‐dependent aggregate formation and cell toxicity , 2004, Journal of neurochemistry.
[84] Z. Qin,et al. Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes , 2012, Acta Pharmacologica Sinica.
[85] D. Altschuh,et al. Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions. , 2011, Human molecular genetics.
[86] Christopher A. Ross,et al. Huntingtin Spheroids and Protofibrils as Precursors in Polyglutamine Fibrilization* , 2002, The Journal of Biological Chemistry.
[87] P. Mcgeer,et al. Optineurin in Huntington's disease intranuclear inclusions , 2012, Neuroscience Letters.
[88] S. Hersch,et al. Interaction of Huntingtin-Associated Protein with Dynactin P150Glued , 1998, The Journal of Neuroscience.
[89] E. Seeberg,et al. Mutant Huntingtin Impairs Axonal Trafficking in Mammalian Neurons In Vivo and In Vitro , 2004, Molecular and Cellular Biology.
[90] P. Reddy,et al. Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* , 2001, The Journal of Biological Chemistry.
[91] Christopher A Ross,et al. A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. , 2005, Human molecular genetics.
[92] D. Irimia,et al. Multiple phenotypes in Huntington disease mouse neural stem cells , 2012, Molecular and Cellular Neuroscience.
[93] M. Chiang,et al. The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. , 2011, Biochimica et biophysica acta.
[94] F. Fornai,et al. Abnormal morphology of peripheral cell tissues from patients with Huntington disease , 2009, Journal of Neural Transmission.
[95] J. Cooper,et al. Inclusion formation in Huntington's disease R6/2 mouse muscle cultures , 2003, Journal of neurochemistry.
[96] E. Masliah,et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[97] Elena Cattaneo,et al. Normal huntingtin function: an alternative approach to Huntington's disease , 2005, Nature Reviews Neuroscience.
[98] K. Rezvani,et al. Modeling Pathogenesis of Huntington’s Disease with Inducible Neuroprogenitor Cells , 2011, Cellular and Molecular Neurobiology.
[99] R. Richards,et al. Selective neuronal requirement for huntingtin in the developing zebrafish , 2009, Human molecular genetics.
[100] M. Hayden,et al. Testicular degeneration in Huntington disease , 2007, Neurobiology of Disease.
[101] Thomas H Gillingwater,et al. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation , 2004, The European journal of neuroscience.
[102] Wenzhen Duan,et al. Peroxisome-Proliferator-Activated Receptor Gamma Coactivator 1 α Contributes to Dysmyelination in Experimental Models of Huntington's Disease , 2011, The Journal of Neuroscience.
[103] M. Russo,et al. Increased apoptosis, huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects , 2006, Cell Death and Differentiation.
[104] A. Wyttenbach,et al. Neurotoxic protein oligomerisation associated with polyglutamine diseases , 2010, Acta Neuropathologica.
[105] K Dane Wittrup,et al. Stochastic kinetics of intracellular huntingtin aggregate formation , 2006, Nature chemical biology.
[106] G. Bates,et al. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington’s disease , 2007, Journal of neurochemistry.
[107] M. Hayden,et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. , 1997, American journal of human genetics.
[108] Chuan-en Wang,et al. Mutant Huntingtin in Glial Cells Exacerbates Neurological Symptoms of Huntington Disease Mice* , 2010, The Journal of Biological Chemistry.
[109] M. Sherman,et al. Characterization of Proteins Associated with Polyglutamine Aggregates , 2007, Prion.
[110] K. Varani,et al. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[111] Jun-chao Wu,et al. Expression of mutant N-terminal huntingtin fragment (htt552-100Q) in astrocytes suppresses the secretion of BDNF , 2012, Brain Research.
[112] Alexander Hammers,et al. A systematic comparison of kinetic modelling methods generating parametric maps for [11C]-(R)-PK11195 , 2007, NeuroImage.
[113] D. Rubinsztein,et al. Wild type huntingtin reduces the cellular toxicity of mutant huntingtin in mammalian cell models of Huntington's disease , 2001, Journal of medical genetics.
[114] Denis Soulet,et al. Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion. , 2009, Human molecular genetics.
[115] D. Rubinsztein,et al. Deletion of the Huntingtin Polyglutamine Stretch Enhances Neuronal Autophagy and Longevity in Mice , 2010, PLoS genetics.
[116] D. Dickson,et al. Expanded-Polyglutamine Huntingtin Protein Suppresses the Secretion and Production of a Chemokine (CCL5/RANTES) by Astrocytes , 2008, The Journal of Neuroscience.
[117] A. Morton,et al. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death , 2008, Brain Research Bulletin.
[118] M. Hendrix,et al. Tissue culture of epithelial cells from esophageal specialized columnar epithelium (Barrett's esophagus) , 1992, Digestive Diseases and Sciences.
[119] Z. Qin,et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[120] R. Wetzel,et al. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. , 2001, Journal of molecular biology.
[121] Chuan-en Wang,et al. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms , 2009, Proceedings of the National Academy of Sciences.
[122] T. Hortobágyi,et al. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders , 2011, Acta Neuropathologica.
[123] S. Yamanaka,et al. Recent Stem Cell Advances: Induced Pluripotent Stem Cells for Disease Modeling and Stem Cell–Based Regeneration , 2010, Circulation.
[124] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[125] Steve D. M. Brown,et al. α-Synuclein levels modulate Huntington's disease in mice. , 2012, Human molecular genetics.
[126] M. Hayden,et al. Huntingtin is required for normal hematopoiesis. , 2000, Human molecular genetics.
[127] E. Cattaneo,et al. Role of brain-derived neurotrophic factor in Huntington's disease , 2007, Progress in Neurobiology.
[128] Mark Turmaine,et al. Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.
[129] S. Floresco,et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.
[130] D. Rubinsztein,et al. Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.
[131] David Blum,et al. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics , 2003, The Lancet Neurology.
[132] L. K. Baker,et al. Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.
[133] L. Thompson,et al. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation , 2006, Mechanisms of Ageing and Development.
[134] F. Cicchetti,et al. The role of immunity in Huntington's disease , 2011, Molecular Psychiatry.
[135] A. Hackam,et al. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. , 1999, Human molecular genetics.
[136] K. Hoyt,et al. Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease , 2007, Neurobiology of Disease.
[137] G. Bates,et al. Huntingtin aggregation and toxicity in Huntington's disease , 2003, The Lancet.
[138] Fumiaki Tanaka,et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. , 2003, Human molecular genetics.
[139] M. MacDonald,et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease , 2003, American journal of medical genetics. Part A.
[140] Blair R. Leavitt,et al. Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.
[141] C. Ross,et al. Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics. , 2009, Parkinsonism & related disorders.
[142] Xiao-Bo Sun,et al. Overexpression of F(0)F(1)-ATP synthase alpha suppresses mutant huntingtin aggregation and toxicity in vitro. , 2009, Biochemical and biophysical research communications.
[143] S. W. Davies,et al. Formation of polyglutamine inclusions in non-CNS tissue. , 1999, Human molecular genetics.
[144] M. Hayden,et al. Wild‐type huntingtin protects neurons from excitotoxicity , 2006, Journal of neurochemistry.
[145] Austin G Smith,et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity , 2012, Neurobiology of Disease.
[146] P. Muchowski. Protein Misfolding, Amyloid Formation, and Neurodegeneration A Critical Role for Molecular Chaperones? , 2002, Neuron.
[147] S. W. Davies,et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.
[148] S. Zeitlin,et al. Expression of the Huntingtin-associated protein 1 gene in the developing and adult mouse , 2000, Neuroscience Letters.
[149] L. Raymond,et al. Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.
[150] G. Bates,et al. Formation of Polyglutamine Inclusions in a Wide Range of Non-CNS Tissues in the HdhQ150 Knock-In Mouse Model of Huntington's Disease , 2009, PloS one.
[151] E. Cattaneo,et al. Modeling huntington’s disease in cells, flies, and mice , 2001, Molecular Neurobiology.
[152] Osamu Onodera,et al. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. , 2008, Human molecular genetics.
[153] V. Silani,et al. Huntington's disease: The current state of research with peripheral tissues , 2009, Experimental Neurology.
[154] M. Pennuto,et al. Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. , 2009, Human Molecular Genetics.
[155] J. Olson,et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. , 2002, Human molecular genetics.
[156] P. Paganetti,et al. Inducible mutant huntingtin expression in HN10 cells reproduces Huntington's disease-like neuronal dysfunction , 2009, Molecular Neurodegeneration.
[157] Jiandie D. Lin,et al. Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.
[158] E. Kavanagh,et al. Caspase signalling controls microglia activation and neurotoxicity , 2011, Nature.